Skip to main content
Erschienen in: Clinical and Experimental Nephrology 5/2011

01.10.2011 | Original Article

Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function

verfasst von: Takahito Moriyama, Nobuyuki Amamiya, Ayami Ochi, Yuki Tsuruta, Ari Shimizu, Chiari Kojima, Mitsuyo Itabashi, Takashi Takei, Keiko Uchida, Kosaku Nitta

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

There are few reports analyzing the effects of angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) on the long-term renal survival of advanced immunoglobulin A nephropathy (IgAN) patients.

Patients and methods

In this retrospective cohort analysis, we divided 66 IgAN patients with an estimated glomerular filtration rate (eGFR) <60 ml/min into three groups: ACEI group (n = 20, treated with ACEIs), ARB group (n = 23, treated with ARBs), and control group (n = 23, treated with antiplatelet agents), and analyzed the clinical and histological background, renal survival rate until the primary endpoint of 50% decrease of eGFR from baseline, and the secondary endpoint of progression to end-stage renal disease, and the risk factors for progression.

Results

The clinical and histological background without serum IgA and C3 were not significantly different among the three groups. The renal survival rate until the primary and secondary endpoints was significantly higher in the ACEI and ARB groups than in the control group. The independent risk factors for progression were higher mean blood pressure (hazard ratio [HR] 1.76, P = 0.04), higher histological grade (HR 2.54, P = 0.0184) at baseline, and without ACEIs or ARBs (HR 7.09, P = 0.001), but decreased proteinuria and blood pressure. The risk factors with resistance to ACEIs or ARBs were higher blood pressure and lower eGFR at baseline. There was no difference regarding the survival rate and the risk for progression between ACEI s and ARBs.

Conclusion

ACEIs or ARBs were effective for long-term renal survival of advanced IgAN, although proteinuria and blood pressure did not decrease.
Literatur
1.
Zurück zum Zitat Berger J, Hinglais N. Les dépôts intercapillaries d’IgA-IgG. J Urol Nephrol. 1968;74:694–5. Berger J, Hinglais N. Les dépôts intercapillaries d’IgA-IgG. J Urol Nephrol. 1968;74:694–5.
3.
Zurück zum Zitat Locatelli F, Del Vecchio L, Pozzi C. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors. Nat Clin Pract Nephrol. 2006;2:24–31.CrossRefPubMed Locatelli F, Del Vecchio L, Pozzi C. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors. Nat Clin Pract Nephrol. 2006;2:24–31.CrossRefPubMed
4.
Zurück zum Zitat Ballardie FW. Quantitative appraisal of treatment options for IgA nephropathy. J Am Soc Nephrol. 2007;18:2806–9.CrossRefPubMed Ballardie FW. Quantitative appraisal of treatment options for IgA nephropathy. J Am Soc Nephrol. 2007;18:2806–9.CrossRefPubMed
5.
Zurück zum Zitat Komatsu T, Fujimoto S, Hara S, Fukuda A, Fukudome K, Yamada K, et al. Recent therapeutic strategies improve renal outcome in patients with IgA nephropathy. Am J Nephrol. 2009;30:19–25.CrossRefPubMed Komatsu T, Fujimoto S, Hara S, Fukuda A, Fukudome K, Yamada K, et al. Recent therapeutic strategies improve renal outcome in patients with IgA nephropathy. Am J Nephrol. 2009;30:19–25.CrossRefPubMed
6.
Zurück zum Zitat Asaba K, Yojo A, Onozato ML, Kinugasa S, Miyazaki H, Miyashita K, et al. Long-term renal prognosis of IgA nephropathy with therapeutic trend shifts. Intern Med. 2009;48:83–90.CrossRef Asaba K, Yojo A, Onozato ML, Kinugasa S, Miyazaki H, Miyashita K, et al. Long-term renal prognosis of IgA nephropathy with therapeutic trend shifts. Intern Med. 2009;48:83–90.CrossRef
7.
Zurück zum Zitat Cheng J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trial. Int J Clin Pract. 2009;63:80–8.CrossRef Cheng J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trial. Int J Clin Pract. 2009;63:80–8.CrossRef
8.
Zurück zum Zitat Dillon JJ. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy. Semin Nephrol. 2004;24:218–24.CrossRefPubMed Dillon JJ. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy. Semin Nephrol. 2004;24:218–24.CrossRefPubMed
9.
Zurück zum Zitat Joh K. Proposal for a new histological classification of IgA nephropathy in Japan and a preliminary report of the international clinic-pathological classification of IgA nephropathy. Jpn J Nephrol. 2008;50:448–55. Joh K. Proposal for a new histological classification of IgA nephropathy in Japan and a preliminary report of the international clinic-pathological classification of IgA nephropathy. Jpn J Nephrol. 2008;50:448–55.
10.
Zurück zum Zitat Praga M, Gutiérrez E, González E, Morales E, Hernández E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14:1578–83.CrossRefPubMed Praga M, Gutiérrez E, González E, Morales E, Hernández E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14:1578–83.CrossRefPubMed
11.
Zurück zum Zitat Kanno Y, Okada H, Yamaji Y, Nakazato Y, Suzuki H. Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation. QJM. 2005;98:199–203.CrossRefPubMed Kanno Y, Okada H, Yamaji Y, Nakazato Y, Suzuki H. Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation. QJM. 2005;98:199–203.CrossRefPubMed
12.
Zurück zum Zitat Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, et al. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol. 2000;20:373–9.CrossRefPubMed Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, et al. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol. 2000;20:373–9.CrossRefPubMed
13.
Zurück zum Zitat Li PKT, Leung CB, Chow KM, Cheng YL, Fung SKS, Mak SK, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751–60.CrossRefPubMed Li PKT, Leung CB, Chow KM, Cheng YL, Fung SKS, Mak SK, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751–60.CrossRefPubMed
14.
Zurück zum Zitat Woo KT, Chan CM, Tan HK, Choong HL, Foo M, Vathsala A, et al. Beneficial effects of high-dose losartan in IgA nephritis. Clin Nephrol. 2009;71:617–24.CrossRefPubMed Woo KT, Chan CM, Tan HK, Choong HL, Foo M, Vathsala A, et al. Beneficial effects of high-dose losartan in IgA nephritis. Clin Nephrol. 2009;71:617–24.CrossRefPubMed
15.
Zurück zum Zitat Shimizu A, Takei T, Uchida K, Tsuchiya K, Nitta K. Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertens Res. 2008;31:1711–7.CrossRefPubMed Shimizu A, Takei T, Uchida K, Tsuchiya K, Nitta K. Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertens Res. 2008;31:1711–7.CrossRefPubMed
16.
Zurück zum Zitat Tomino Y, Kawamura T, Kimura K, Endoh M, Hosoya T, Horikoshi S, et al. Antiproteinuric effect of olmesartan in patients with IgA nephropathy. J Nephrol. 2009;22:224–31.PubMed Tomino Y, Kawamura T, Kimura K, Endoh M, Hosoya T, Horikoshi S, et al. Antiproteinuric effect of olmesartan in patients with IgA nephropathy. J Nephrol. 2009;22:224–31.PubMed
17.
Zurück zum Zitat Woo KT, Lau YK, Wong KS, Chiang GSC. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int. 2000;58:2485–91.CrossRefPubMed Woo KT, Lau YK, Wong KS, Chiang GSC. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int. 2000;58:2485–91.CrossRefPubMed
18.
Zurück zum Zitat Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38:18–25.CrossRefPubMed Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38:18–25.CrossRefPubMed
19.
Zurück zum Zitat Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, et al. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertens Res. 2004;27:963–70.CrossRefPubMed Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, et al. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertens Res. 2004;27:963–70.CrossRefPubMed
20.
Zurück zum Zitat Horita Y, Taura K, Taguchi T, Furusu A, Kohno S. Aldosterone breakthrough during therapy with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology. 2006;11:462–6.CrossRefPubMed Horita Y, Taura K, Taguchi T, Furusu A, Kohno S. Aldosterone breakthrough during therapy with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology. 2006;11:462–6.CrossRefPubMed
21.
Zurück zum Zitat Miura N, Imai H, Kikuchi S, Hayashi S, Endoh Kawamura T, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460–6.CrossRefPubMed Miura N, Imai H, Kikuchi S, Hayashi S, Endoh Kawamura T, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460–6.CrossRefPubMed
22.
Zurück zum Zitat Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.CrossRefPubMed Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.CrossRefPubMed
23.
Zurück zum Zitat Hotta O. Use of corticosteroids, other immunosuppressive therapies, and tonsillectomy in the treatment of IgA nephropathy. Semin Nephrol. 2004;3:244–55.CrossRef Hotta O. Use of corticosteroids, other immunosuppressive therapies, and tonsillectomy in the treatment of IgA nephropathy. Semin Nephrol. 2004;3:244–55.CrossRef
24.
25.
Zurück zum Zitat Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients to receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis. 1994;23:247–54.CrossRefPubMed Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients to receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis. 1994;23:247–54.CrossRefPubMed
26.
Zurück zum Zitat Woo KT, Lau YK, Chan CM, Wong KS. Angiotensin-converting enzyme inhibitor versus angiotensin 2 receptor antagonist therapy and the influence of angiotensin-converting enzyme gene polymorphism in IgA nephritis. Ann Acad Med. 2008;37:372–6. Woo KT, Lau YK, Chan CM, Wong KS. Angiotensin-converting enzyme inhibitor versus angiotensin 2 receptor antagonist therapy and the influence of angiotensin-converting enzyme gene polymorphism in IgA nephritis. Ann Acad Med. 2008;37:372–6.
Metadaten
Titel
Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function
verfasst von
Takahito Moriyama
Nobuyuki Amamiya
Ayami Ochi
Yuki Tsuruta
Ari Shimizu
Chiari Kojima
Mitsuyo Itabashi
Takashi Takei
Keiko Uchida
Kosaku Nitta
Publikationsdatum
01.10.2011
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 5/2011
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0455-8

Weitere Artikel der Ausgabe 5/2011

Clinical and Experimental Nephrology 5/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.